Analyzing Nexentis Technologies (NASDAQ:NXTS) & Royalty Pharma (NASDAQ:RPRX)

Nexentis Technologies (NASDAQ:NXTS) and Royalty Pharma (NASDAQ:RPRX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Institutional and Insider Ownership

61.2% of Nexentis Technologies shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 6.5% of Nexentis Technologies shares are owned by company insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Nexentis Technologies has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Profitability

This table compares Nexentis Technologies and Royalty Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-304.79%	-178.91%
Royalty Pharma	32.14%	30.01%	14.91%

Earnings & Valuation

This table compares Nexentis Technologies and Royalty Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	$210,000.00	3.88	-$4.00 million	($96.07)	-0.01
Royalty Pharma	$2.38 billion	15.66	$770.95 million	$1.45	44.66

Royalty Pharma has higher revenue and earnings than Nexentis Technologies. Nexentis Technologies is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Nexentis Technologies and Royalty Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1	0	0	0	1.00
Royalty Pharma	0	0	8	0	3.00

Royalty Pharma has a consensus price target of $61.57, indicating a potential downside of 4.92%. Given Royalty Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Royalty Pharma is more favorable than Nexentis Technologies.

Summary

Royalty Pharma beats Nexentis Technologies on 12 of the 14 factors compared between the two stocks.

About Nexentis Technologies

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.